The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling

Cancer

Volumn 119, Issue 5, 2013, Pages 955-962

  Vencken, Peggy M L H ^a   Kriege, Mieke ^a   Hooning, Maartje ^a   Menke Pluymers, Marian B ^a   Heemskerk Gerritsen, Bernadette A M ^a   Van Doorn, Lena C ^a   Collée, Margriet M ^a   Jager, Agnes ^a   Van Montfort, Cees ^a   Burger, Curt W ^a   Seynaeve, Caroline ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

BRCA; contralateral breast cancer; ovarian cancer; primary breast cancer; risk reducing mastectomy

Indexed keywords

PACLITAXEL; PLATINUM COMPLEX;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC CORRELATION; HETEROZYGOSITY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; HETEROZYGOTE; HUMANS; INFANT; MIDDLE AGED; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; OVARIAN NEOPLASMS; RISK; YOUNG ADULT;

EID: 84874279104     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27839     Document Type: Article

References (42)

1. Van der Kolk DM, de Bock GH, Leegte BK, et al. Penetrance of breast cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat. 2010; 124: 643-651.
2. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998; 62: 676-689.
3. Chen S, Parmigiani G,. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007; 25: 1329-1333.
4. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999; 91: 1475-1479.
5. Antoniou AC, Beesley J, McGuffog L, et al. Common breast cancer susceptibility alleles and the risk of BC for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010; 70: 9742-9754.
6. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72: 1117-1130. Erratum in Am J Hum Genet. 2003;73:709.
7. Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009; 27: 5887-5892.
8. Metcalfe KA, Lynch HT, Ghadirian P, et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005; 96: 222-226.
9. Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II BC. J Clin Oncol. 2006; 24: 2437-2443.
10. Schwartz MD, Lerman C, Brogan B, et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol. 2004; 22: 1823-1829.
11. Verhoog LC, Brekelmans CT, Seynaeve C, Meijers-Heijboer EJ, Klijn JG,. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer. 2000; 83: 384-386.
12. Narod SA,. BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol. 2010; 7: 702-707.
13. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010; 304: 967-975.
14. Rijnsburger AJ, Obdeijn IM, Kaas R, et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol. 2010; 28: 5265-5273.
15. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004; 351: 427-437.
16. Tyagi AK, Agarwal C, Chan DC, Agarwal R,. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep. 2004; 11: 493-499.
17. Menendez JA, Vellon L, Colomer R, Lupu R,. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Int J Cancer. 2005; 115: 19-35.
18. Lostumbo L, Carbine N, Wallace J,. Prophylactic mastectomy for the prevention of breast cancer [serial online]. Cochrane Database Syst Rev. 2010;(11):CD002748.
19. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004; 22: 1055-1062.
20. Meijers-Heijboer H, van Geel B, van Putten WL,. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001; 345: 159-164.
21. Beattie MS, Crawford B, Lin F, Vittinghoff E, Ziegler J,. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biomarkers. 2009; 13: 51-56.
22. Cuzick J, Decensi A, Arun B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011; 12: 496-503.
23. Kramer JL, Velazques IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH,. Prophylactic oophorectomy reduces BC penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol. 2005; 23: 8629-8635.
24. Kauff ND, Domcheck SM, Friebel TM, et al. RRSO for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008; 26: 1331-1337.
25. Rebbeck TR, Kauff ND, Domchek SM,. Meta-analysis of risk reduction estimates associated with RRSO in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009; 101: 80-87.
26. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005; 23: 7491-7496.
27. Kurian AW, Sigal BM, Plevritis SK,. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol. 2010; 28: 222-231.
28. Allain DC, Sweet K, Agnese DM,. Management options after prophylactic surgeries in women with BRCA mutations: a review. Cancer Control. 2007; 14: 330-337.
29. Quinn JE, Carser JE, James CR, Kennedy RD, Harkin DP,. BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol. 2009; 113: 134-142.
30. Tan D, Rothermundt C, Thomas K, et al. BCRAness syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008; 26: 5530-5536.
31. Vencken PM, Kriege M, Hoogwerf D, et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol. 2011; 22: 1346-1352.
32. Brekelmans CTM, Tilanus-Linthorst MMA, Seynaeve C, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer. 2007; 43: 867-876.
33. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD,. A note on competing risks in survival data analysis. Br J Cancer. 2004; 91: 1229-1235.
34. Silver DP, Richardson AL, Eklund SC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010; 28: 1145-1153.
35. Nathanson KL, Domchek SM,. Therapeutic approaches for women predisposed to breast cancer. Annu Rev Med. 2011; 62: 295-306.
36. Reding KW, Bernstein JL, Langholz BM, et al. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of CBC. Breast Cancer Res Treat. 2010; 123: 491-498.
37. Kriege M, Brekelmans CT, Peterse H, et al. Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer. Breast Cancer Res Treat. 2007; 102: 357-363.
38. Tilanus-Linthorst MM, Obdeijn IM, Bartels KC, de Koning HJ, Oudkerk M,. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat. 2000; 63: 53-60.
39. Hoover DJ, Paragi PR, Sanroro E, Schafer S, Chamberlain RS,. Prophylactic mastectomy in high risk patients: a practice-based review of the indications. Do we follow guidelines? Breast Dis. 2010; 31: 19-27.
40. Gahm J, Wickman M, Brandberg Y,. Bilateral prophylactic mastectomy in women with inherited risk of breast cancer-prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret 2 years after surgery. Breast. 2010; 19: 462-469.
41. Metcalfe KA, Lubinski J, Ghadirian P, et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol. 2008; 26: 1093-1097.
42. Rijnsburger AJ, van Oortmarssen GJ, Boer R, et al. Mammography benefit in the Canadian National Breast Screening Study-2: a model evaluation. Int J Cancer. 2004; 110: 756-762.